News

Press Releases

Aug 08, 2022

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Jun 11, 2022

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Jun 11, 2022

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

Jun 08, 2022

CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

View All Press

Presentations

Aug 08, 2022

8/8/22 Release

Jul 18, 2022

CRISPR Therapeutics Corporate Presentation

Jun 21, 2022

Innovation Day Presentation

Jun 12, 2022

EHA 2022 (Exa-cel)

View All Presentations

Events

Wednesday, June 13, 2018 8:00 a.m. PT

CRISPR Therapeutics at Goldman Sachs 39th Annual Global Healthcare Conference

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.

Continue